Safety of the intravenous administration of neurotensin-polyplex nanoparticles in BALB/c mice

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 10, Issue 4, 2014, Pages 745-754

  Hernandez, Maria E ^a   Rembao, Jesus D ^b   Hernandez Baltazar, Daniel ^f   Castillo Rodriguez, Rosa A ^f   Tellez Lopez, Victor M ^f   Flores Martinez, Yazmin M ^f   Orozco Barrios, Carlos E ^f   Rubio, Hector A ^c   Sánchez García, Aurora ^b   Ayala Davila, Jose ^f   Arango Rodriguez, Martha L ^d   Pavón, Lenin ^a   Mejia Castillo, Teresa ^f   Forgez, Patricia ^e   Martinez Fong, Daniel ^f  

^a Department of Psychoimmunology INPRF   (Mexico)

^b NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

^c UNIVERSIDAD AUTÓNOMA DE YUCATÁN   (Mexico)

^d Facultad de Medicina Clinica Alemana Universidad del Desarrollo   (Chile)

^e HÔPITAL SAINT ANTOINE   (France)

^f DEPARTAMENTO DE FÍSICA   (Mexico)

Author keywords

Biosafety; Cytotoxicity; Nanomaterials; Pro inflammatory cytokines

Indexed keywords

AMINO ACIDS; BODY FLUIDS; CARBON TETRACHLORIDE; CELLS; CYTOLOGY; CYTOTOXICITY; GLYCOPROTEINS; MAMMALS; MEDICAL NANOTECHNOLOGY; NANOSTRUCTURED MATERIALS; NEURODEGENERATIVE DISEASES; PHOSPHATASES; PLANTS (BOTANY);

ACUTE INFLAMMATORY RESPONSE; ALKALINE PHOSPHATASE; BIOSAFETY; INTRAVENOUS ADMINISTRATION; INTRAVENOUS INJECTIONS; MONONUCLEAR PHAGOCYTE SYSTEMS; PRO-INFLAMMATORY CYTOKINES; TUMOR NECROSIS FACTOR ALPHA;

GENES;

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CARBON TETRACHLORIDE; CARRAGEENAN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; NANOCARRIER; NEUROTENSIN POLYPLEX; PROPIDIUM IODIDE; SERUM AMYLOID A; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; NANOPARTICLE; NEUROTENSIN RECEPTOR; NEUROTENSIN TYPE 1 RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG SAFETY; GENE EXPRESSION; INFLAMMATION; INTESTINE CELL; MALE; MONONUCLEAR PHAGOCYTE; MOUSE; NONHUMAN; REPORTER GENE; ANIMAL; BIOSYNTHESIS; GENE THERAPY; GENE TRANSFER; GENETICS; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; PARKINSON DISEASE; PROCEDURES; SAFETY;

ADMINISTRATION, INTRAVENOUS; ANIMALS; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; MICE; NANOPARTICLES; PARKINSON DISEASE; RECEPTORS, NEUROTENSIN; SAFETY;

EID: 84900342557     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2013.11.013     Document Type: Article

References (50)

1. Alvarez-Maya I., Navarro-Quiroga I., Meraz-Rios M.A., Aceves J., Martinez-Fong D. In vivo gene transfer to dopamine neurons of rat substantia nigra via the high-affinity neurotensin receptor. Mol Med 2001, 7:186-192.
2. Martinez-Fong D., Navarro-Quiroga I. Synthesis of a non-viral vector for gene transfer via the high-affinity neurotensin receptor. Brain Res Brain Res Protoc 2000, 6:13-24.
3. Martinez-Fong D., Navarro-Quiroga I., Ochoa I., Alvarez-Maya I., Meraz M.A., Luna J., et al. Neurotensin-SPDP-poly-L-lysine conjugate: a nonviral vector for targeted gene delivery to neural cells. Brain Res Mol Brain Res 1999, 69:249-262.
4. Navarro-Quiroga I., Antonio Gonzalez-Barrios J., Barron-Moreno F., Gonzalez-Bernal V., Martinez-Arguelles D.B., Martinez-Fong D. Improved neurotensin-vector-mediated gene transfer by the coupling of hemagglutinin HA2 fusogenic peptide and Vp1 SV40 nuclear localization signal. Brain Res Mol Brain Res 2002, 105:86-97.
5. Hernandez-Baltazar D., Martinez-Fong D., Trudeau L.E. Optimizing NTS-polyplex as a tool for gene transfer to cultured dopamine neurons. PLoS One 2012, 7:e51341.
6. Arango-Rodriguez M.L., Navarro-Quiroga I., Gonzalez-Barrios J.A., Martinez-Arguelles D.B., Bannon M.J., Kouri J., et al. Biophysical characteristics of neurotensin polyplex for in vitro and in vivo gene transfection. Biochim Biophys Acta 2006, 1760:1009-1020.
7. Martinez-Fong D., Bannon M.J., Trudeau L.E., Gonzalez-Barrios J.A., Arango-Rodriguez M.L., Hernandez-Chan N.G., et al. NTS-Polyplex: a potential nanocarrier for neurotrophic therapy of Parkinson's disease. Nanomedicine 2012, 8:1052-1069.
8. Gonzalez-Barrios J.A., Lindahl M., Bannon M.J., Anaya-Martinez V., Flores G., Navarro-Quiroga I., et al. Neurotensin polyplex as an efficient carrier for delivering the human GDNF gene into nigral dopamine neurons of hemiparkinsonian rats. Mol Ther 2006, 14:857-865.
9. Sadoul J.L., Checler F., Kitabgi P., Rostene W., Javoy-Agid F., Vincent J.P. Loss of high affinity neurotensin receptors in substantia nigra from parkinsonian subjects. Biochem Biophys Res Commun 1984, 125:395-404.
10. Szigethy E., Beaudet A. Correspondence between high affinity 125I-neurotensin binding sites and dopaminergic neurons in the rat substantia nigra and ventral tegmental area: a combined radioautographic and immunohistochemical light microscopic study. J Comp Neurol 1989, 279:128-137.
11. Souaze F., Viardot-Foucault V., Roullet N., Toy-Miou-Leong M., Gompel A., Bruyneel E., et al. Neurotensin receptor 1 gene activation by the Tcf/beta-catenin pathway is an early event in human colonic adenomas. Carcinogenesis 2006, 27:708-716.
12. Dupouy S., Mourra N., Doan V.K., Gompel A., Alifano M., Forgez P. The potential use of the neurotensin high affinity receptor 1 as a biomarker for cancer progression and as a component of personalized medicine in selective cancers. Biochimie 2011, 93:1369-1378.
13. Wu Z., Martinez-Fong D., Tredaniel J., Forgez P. Neurotensin and its high affinity receptor 1 as a potential pharmacological target in cancer therapy. Front Endocrinol (Lausanne) 2012, 3:184.
14. Rubio-Zapata H.A., Rembao-Bojorquez J.D., Arango-Rodriguez M.L., Dupouy S., Forgez P., Martinez-Fong D. NT-polyplex: a new tool for therapeutic gene delivery to neuroblastoma tumors. Cancer Gene Ther 2009, 16:573-584.
15. Castillo-Rodriguez R., Arango-Rodriguez M., Escobedo L., Rubio-Zapata H., Tellez-Lopez V., Mejia-Castillo T., et al. Neurotensin-Polyplex as a Potential Tool in Gene Therapy for Human Breast Cancer. Eur J Cancer 2012, 48:S93.
16. Nie S. Understanding and overcoming major barriers in cancer nanomedicine. Nanomedicine (Lond) 2010, 5:523-528.
17. Ward C.M., Read M.L., Seymour L.W. Systemic circulation of poly(L-lysine)/DNA vectors is influenced by polycation molecular weight and type of DNA: differential circulation in mice and rats and the implications for human gene therapy. Blood 2001, 97:2221-2229.
18. Neun B.W., Dobrovolskaia M.A. Method for analysis of nanoparticle hemolytic properties in vitro. Methods Mol Biol 2011, 697:215-224.
19. Verbaan F.J., Oussoren C., van Dam I.M., Takakura Y., Hashida M., Crommelin D.J., et al. The fate of poly(2-dimethyl amino ethyl)methacrylate-based polyplexes after intravenous administration. Int J Pharm 2001, 214:99-101.
20. Pack D.W., Hoffman A.S., Pun S., Stayton P.S. Design and development of polymers for gene delivery. Nat Rev Drug Discov 2005, 4:581-593.
21. Owens D.E., Peppas N.A. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 2006, 307:93-102.
22. Alexis F., Pridgen E., Molnar L.K., Farokhzad O.C. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 2008, 5:505-515.
23. Mendez M., Souaze F., Nagano M., Kelly P.A., Rostene W., Forgez P. High affinity neurotensin receptor mRNA distribution in rat brain and peripheral tissues. Analysis by quantitative RT-PCR. J Mol Neurosci 1997, 9:93-102.
24. Carraway R., Leeman S.E. Characterization of radioimmunoassayable neurotensin in the rat. Its differential distribution in the central nervous system, small intestine, and stomach. J Biol Chem 1976, 251:7045-7052.
25. Saito Y., Higuchi Y., Kawakami S., Yamashita F., Hashida M. Immunostimulatory characteristics induced by linear polyethyleneimine-plasmid DNA complexes in cultured macrophages. Hum Gene Ther 2009, 20:137-145.
26. Kawakami S., Ito Y., Charoensit P., Yamashita F., Hashida M. Evaluation of proinflammatory cytokine production induced by linear and branched polyethylenimine/plasmid DNA complexes in mice. J Pharmacol Exp Ther 2006, 317:1382-1390.
27. Plank C., Mechtler K., Szoka F.C., Wagner E. Activation of the complement system by synthetic DNA complexes: a potential barrier for intravenous gene delivery. Hum Gene Ther 1996, 7:1437-1446.
28. Higashisaka K., Yoshioka Y., Yamashita K., Morishita Y., Fujimura M., Nabeshi H., et al. Acute phase proteins as biomarkers for predicting the exposure and toxicity of nanomaterials. Biomaterials 2011, 32:3-9.
29. Sakurai H., Kawabata K., Sakurai F., Nakagawa S., Mizuguchi H. Innate immune response induced by gene delivery vectors. Int J Pharm 2008, 354:9-15.
30. Zhu J., Huang X., Yang Y. The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice. J Clin Invest 2009, 119:2388-2398.
31. Sotelo-Felix J.I., Martinez-Fong D., Muriel De la Torre P. Protective effect of carnosol on CCl(4)-induced acute liver damage in rats. Eur J Gastroenterol Hepatol 2002, 14:1001-1006.
32. Sotelo-Felix J.I., Martinez-Fong D., Muriel P., Santillan R.L., Castillo D., Yahuaca P. Evaluation of the effectiveness of Rosmarinus officinalis (Lamiaceae) in the alleviation of carbon tetrachloride-induced acute hepatotoxicity in the rat. J Ethnopharmacol 2002, 81:145-154.
33. Winsten S., Cehelyk B. A rapid micro diazo technique for measuring total bilirubin. Clin Chim Acta 1969, 25:441-446.
34. Morris C.J. Carrageenan-induced paw edema in the rat and mouse. Methods Mol Biol 2003, 225:115-121.
35. Liu F., Shollenberger L.M., Conwell C.C., Yuan X., Huang L. Mechanism of naked DNA clearance after intravenous injection. J Gene Med 2007, 9:613-619.
36. Yuan H., Li L., Zheng W., Wan J., Ge P., Li H., et al. Antidiabetic drug metformin alleviates endotoxin-induced fulminant liver injury in mice. Int Immunopharmacol 2012, 12:682-688.
37. Morris M., Li L. Molecular mechanisms and pathological consequences of endotoxin tolerance and priming. Arch Immunol Ther Exp (Warsz) 2012, 60:13-18.
38. Saada S., Marget P., Fauchais A.L., Lise M.C., Chemin G., Sindou P., et al. Differential expression of neurotensin and specific receptors, NTSR1 and NTSR2, in normal and malignant human B lymphocytes. J Immunol 2012, 189:5293-5303.
39. Merkel O.M., Librizzi D., Pfestroff A., Schurrat T., Buyens K., Sanders N.N., et al. Stability of siRNA polyplexes from poly(ethylenimine) and poly(ethylenimine)-g-poly(ethylene glycol) under in vivo conditions: effects on pharmacokinetics and biodistribution measured by Fluorescence Fluctuation Spectroscopy and Single Photon Emission Computed Tomography (SPECT) imaging. J Control Release 2009, 138:148-159.
40. Negash A.A., Ramos H.J., Crochet N., Lau D.T., Doehle B., Papic N., et al. IL-1beta production through the NLRP3 inflammasome by hepatic macrophages links hepatitis C virus infection with liver inflammation and disease. PLoS Pathog 2013, 9:e1003330.
41. Rose-John S. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci 2012, 8:1237-1247.
42. He C., Yin L., Tang C., Yin C. Multifunctional polymeric nanoparticles for oral delivery of TNF-alpha siRNA to macrophages. Biomaterials 2013, 34:2843-2854.
43. Erickson M.A., Banks W.A. Cytokine and chemokine responses in serum and brain after single and repeated injections of lipopolysaccharide: multiplex quantification with path analysis. Brain Behav Immun 2011, 25:1637-1648.
44. Spinelle-Jaegle S., Devillier P., Doucet S., Millet S., Banissi C., Diu-Hercend A., et al. Inflammatory cytokine production in interferon-gamma-primed mice, challenged with lipopolysaccharide. Inhibition by SK&F 86002 and interleukin-1 beta-converting enzyme inhibitor. Eur Cytokine Netw 2001, 12:280-289.
45. Bonnet M.E., Erbacher P., Bolcato-Bellemin A.L. Systemic delivery of DNA or siRNA mediated by linear polyethylenimine (L-PEI) does not induce an inflammatory response. Pharm Res 2008, 25:2972-2982.
46. Yew N.S., Zhao H., Wu I.H., Song A., Tousignant J.D., Przybylska M., et al. Reduced inflammatory response to plasmid DNA vectors by elimination and inhibition of immunostimulatory CpG motifs. Mol Ther 2000, 1:255-262.
47. Knuefermann P., Baumgarten G., Koch A., Schwederski M., Velten M., Ehrentraut H., et al. CpG oligonucleotide activates Toll-like receptor 9 and causes lung inflammation in vivo. Respir Res 2007, 8:72.
48. Zhao H., Hemmi H., Akira S., Cheng S.H., Scheule R.K., Yew N.S. Contribution of Toll-like receptor 9 signaling to the acute inflammatory response to nonviral vectors. Mol Ther 2004, 9:241-248.
49. Kisilevsky R., Manley P.N. Acute-phase serum amyloid A: perspectives on its physiological and pathological roles. Amyloid 2012, 19:5-14.
50. Ghezzi P., Sipe J.D. Dexamethasone modulation of LPS, IL-1, and TNF stimulated serum amyloid A synthesis in mice. Lymphokine Res 1988, 7:157-166.